AVAI on OTC
AVAI BIO, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
-$1.7MNet income, fiscal 20262
Compare with Palisades Venture Inc., Corvex, Inc. or AUDDIA INC., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2023
Where the money goes
Where each dollar of revenue went, fiscal 2023
- Cost of revenue100¢$276.3K
Out of $276.3K in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Amortization Expense | $26.1K | $74.3K |
| Consulting Services | $258.4K | $517.7K |
| General and Administrative Expenses | $792.3K | $762.5K |
| Marketing Expenses | $290.6K | $85.2K |
| Professional Fees | $97.9K | $77.4K |
| Rent Expenses | $857 | |
| Research and Development Expenses | $15.0K | |
| Website Expenses | $14.8K | |
| TOTAL OPERATING EXPENSES | $1.5M | $1.5M |
| Debt Forgiveness | $450.0K | |
| Discount on Convertible Note | -$104.4K | -$47.8K |
| Interest on Convertible Note | -$140.0K | -$11.5K |
| Interest on Loan from Related Parties | -$24.9K | |
| NET INCOME (LOSS) FROM OPERATIONS | -$1.7M | -$1.1M |
| NET INCOME (LOSS) | -$1.7M | -$1.1M |
| COMPREHENSIVE INCOME (LOSS) | -$1.7M | -$1.1M |
| NET LOSS PER SHARE: BASIC AND DILUTED | -$0.01 | -$0.01 |
| WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED | 138.0M shares | 128.1M shares |
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Cash and Cash Equivalents | $23.1K | $81.1K | |
| Loan Receivable | $60.1K | ||
| Prepaid Expenses | $6.1K | $12.1K | |
| Total Current Assets | $89.3K | $93.1K | |
| Intangible Assets, Net (Note 6) | $105.5K | $131.6K | |
| Due from Subsidiaries | $377.8K | ||
| Total Other Assets | $483.4K | $131.6K | |
| TOTAL ASSETS | $572.7K | $224.7K | |
| Accounts Payable | $1.6M | $885.3K | |
| Convertible Notes Payable (Note 8) | $500.5K | $391.3K | |
| Loan Payable - Related Parties (Note 7) | $744.4K | $512.1K | |
| Loan Payable (Note 8) | $550.0K | ||
| Total Current Liabilities | $3.4M | $1.8M | |
| Total Liabilities | $3.4M | $1.8M | |
| Preferred stock, $0.001 par value, 20,000,000 shares authorized; 11,300,000 and 11,300,000 common shares issued and outstanding respectively (Note 9) | $11.3K | $11.3K | |
| Preferred stock Series A, $0.001 par value, 5,000 shares authorized; 3,050 and 3,050 shares issued and outstanding, respectively (Note 9) | $15.2K | $15.2K | |
| Common stock, $0.001 par value, 500,000,000 shares authorized; 153,211,252 and 137,363,513 common shares issued and outstanding respectively (Note 9) | $153.2K | $137.4K | |
| Additional Paid in Capital | $2.9M | $2.4M | |
| Accumulated Deficit | -$5.9M | -$4.1M | |
| Total Stockholders Deficit | -$2.8M | -$1.6M | -$1.5M |
| TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT | $572.7K | $224.7K | |
| Preferred Stock, Par or Stated Value Per Share | $0.00 | $0.00 | |
| Preferred Stock, Shares Authorized | 20.0M shares | 20.0M shares | |
| Preferred Stock, Shares Issued | 11.3M shares | 11.3M shares | |
| Preferred Stock, Shares Outstanding | 11.3M shares | 11.3M shares | |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | |
| Common Stock, Shares Authorized | 500.0M shares | 500.0M shares | |
| Common Stock, Shares, Issued | 153.2M shares | 137.4M shares | |
| Common Stock, Shares, Outstanding | 153.2M shares | 137.4M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Net Loss | -$1.7M | -$1.1M |
| Amortization | $26.1K | $74.3K |
| Prepaid Expenses | $6.0K | $103.7K |
| Accounts Payable | $707.6K | -$196.5K |
| Net cash used in Operating Activities | -$1.0M | -$1.2M |
| Additional Paid in Capital | $482.4K | $1.0M |
| Capital Stock | $15.8K | $20.2K |
| Convertible Notes Payable | $109.3K | $190.3K |
| Due from Subsidiaries | -$377.8K | |
| Loan from Related Parties | $232.3K | $105.3K |
| Loan Payable | $550.0K | -$99.0K |
| Loan Receivable | -$60.1K | |
| Preferred Stock | $1.3K | |
| Net cash provided by Financing Activities | $951.9K | $1.2M |
| Net cash increase (decrease) for period | -$57.9K | $80.8K |
Former names
Recent filings
- Aug 13, 202610-Q REPORT 10-Q
- Jul 14, 202610-K REPORT 10-K
- Jun 30, 2026NT 10-K NOTIFICATION OF LATE FILING
- May 8, 20268-K
- Feb 12, 202610-Q REPORT 10-Q
- Feb 9, 20268-K
- Nov 14, 202510-Q REPORT 10-Q
- Nov 4, 20258-K
- Sep 18, 20258-K
- Sep 17, 20258-K
- Aug 12, 202510-Q REPORT 10-Q
- Jul 8, 202510-K REPORT 10-K
- Jun 30, 2025NT 10-K NOTIFICATION OF LATE FILING
- May 13, 2025RW WITHDRAWAL REQUEST
- May 13, 20258-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARAVAI BIO, INC. filings on SEC EDGAR
- 2SEC EDGARAVAI BIO, INC. 10-K for fiscal 2026
- 3SEC EDGARAVAI BIO, INC. filings on SEC EDGAR
- 4SEC EDGARAVAI BIO, INC. 10-K for fiscal 2023
- 5SEC EDGARAVAI BIO, INC. 10-K for fiscal 2019
- 6SEC EDGARAVAI BIO, INC. 10-K for fiscal 2020
- 7SEC EDGARAVAI BIO, INC. 10-K for fiscal 2021
- 8SEC EDGARAVAI BIO, INC. 10-K for fiscal 2022
- 9SEC EDGARAVAI BIO, INC. 10-Q for fiscal 2025
- 10SEC EDGARAVAI BIO, INC. 10-Q for fiscal 2025
- 11SEC EDGARAVAI BIO, INC. 10-Q for fiscal 2026
- 12SEC EDGARAVAI BIO, INC. 10-K for fiscal 2019